.Johnson & Johnson's deprioritization of its transmittable disease pipeline has actually stated yet another target in the form of its own dengue virus vaccine mosnodenvir.Mosnodenvir is designed to block out communications in between 2 dengue virus proteins. The vaccine made it through J&J's choice in 2015 to merge its contagious illness and also vaccination functions, which saw the likes of a late-stage breathing syncytial virus program went down from the Big Pharma's pipe as well as an E. coli vaccine sold off to Sanofi.Mosnodenvir has possessed a rough time in the clinic, along with J&J terminating one trial due to the effect of COVID-19 on application and also pausing recruitment in yet another study in 2022. However the commitment to mosnodenvir seemed to settle in October 2023, when the vaccine was revealed to cause a dose-dependent antiviral effect on the detectability as well as beginning of dengue infection serotype 3 in a period 2 trial.
That data drop doesn't appear to have actually sufficed to save mosnodenvir for long, along with the Big Pharma revealing today that it is actually ceasing a follow-up stage 2 field study. The decision is actually related to a "key reprioritization of the firm's infectious illness R&D collection," included J&J, which pressured that no safety and security concerns had been actually pinpointed." Johnson & Johnson will certainly remain to assist the aggression against dengue by sharing research leads along with the medical neighborhood down the road," the pharma stated in the launch.J&J had been actually investing in dengue for over a many years, featuring releasing a Satellite Facility for Global Wellness Breakthrough at the Duke-NUS Medical College in Singapore in 2022. The facility has actually been focused on speeding up early-stage revelation analysis to "deal with the growing difficulty of flaviviruses" such as dengue and also Zika.